<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31703">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01797718</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT:2012-002477-59</org_study_id>
    <nct_id>NCT01797718</nct_id>
  </id_info>
  <brief_title>Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment</brief_title>
  <acronym>CDGP</acronym>
  <official_title>Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for Paediatric Research, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <authority>Finland: National Advisory Board on Health Care Ethics</authority>
    <authority>Finland: Finnish National Agency for Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Boys with constitutional delay of growth and puberty (CDGP) should be offered evidence-based
      effective and safe treatment option. This study compares the effects of low-dose
      testosterone and aromatase inhibitor letrozole on pubertal progression. The hypothesis is
      that, in boys CDGP showing earliest signs of puberty, peroral letrozole (2.5 mg/d for 6 mo)
      induces faster biochemical and clinical progression of puberty as compared to low-dose
      intramuscular testosterone Rx (~1mg/kg/mo for 6 mo). In addition, 10 or more boys who select
      watchful waiting instead of medication will provide background data on the natural
      progression of CDGP, and their data will not be used in primary statistical comparisons.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>testicular volume</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Testes will be measured with a ruler to the nearest millimeter and volume will be calculated at 0, 6, and 12 mo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical and biochemical measures of pubertal progression</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Activity of the hypothalamic-pituitary-gonadal axis, evaluated by
genital and pubic hair stage of puberty according to Tanner;
growth velocity (cm/yr);
basal and gonadotropin-releasing hormone (GnRH)-stimulated gonadotropin levels;
urinary luteinizing hormone levels;
testosterone;
inhibin B;
anti-mullerian hormone (AMH)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone health</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Several endpoints related to bone health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychosocial well-being</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Psycho-social well-being will assessed with questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puberty-related metabolical and clinical changes</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biochemical and metabolical changes will be compared btw testosterone and letrozole treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Constitutional Delay of Growth and Puberty</condition>
  <arm_group>
    <arm_group_label>Testosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>~1mg/kg every 4 weeks for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5mg daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>1mg/kg every 4 weeks for 6 months</description>
    <arm_group_label>Testosterone</arm_group_label>
    <other_name>Sustanon 250</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>2.5mg daily for 6 months</description>
    <arm_group_label>Letrozole</arm_group_label>
    <other_name>Letrozole Bluefish</other_name>
    <other_name>Letrozole Orion</other_name>
    <other_name>Letrozole Accord</other_name>
    <other_name>Letrozole Sandoz</other_name>
    <other_name>Femar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Constitutional delay of growth and puberty

          -  Age 14 years or more

          -  mean testicular volume 2.5 ml or more and less than 4 ml

          -  serum testosterone level less than 5 nM OR

        as above, but serum testosterone 1 nM or more with normal DHEAS level, even if the mean
        testicular volume is less than 2.5 ml

        Exclusion Criteria:

          -  Chronic diseases

          -  Primary or secondary hypogonadism

          -  Chromosomal anomalies

          -  Chronic medication that potentially adversely affects bone mineralization (excluding
             inhaled corticosteroid treatment)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taneli Raivio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matti Hero, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tero Varimo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Päivi Miettinen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorma Toppari, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Turku</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harri Niinikoski, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Turku</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kirsi Näntö-Salonen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Turku</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanna Huopio, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kuopio University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taneli Raivio, MD, PhD</last_name>
    <phone>+358-9-4711</phone>
    <email>taneli.raivio@helsinki.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matti Hero, MD, PhD</last_name>
    <phone>+358-9-4711</phone>
    <email>matti.hero@hus.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matti Hero, MD, PhD</last_name>
      <phone>+35894711</phone>
      <email>matti.hero@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuopio University Central Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Raimo Voutilainen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanna Huopio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jorma Toppari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 30, 2014</lastchanged_date>
  <firstreceived_date>February 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Tero Varimo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Puberty</keyword>
  <keyword>Constitutional</keyword>
  <keyword>Delay</keyword>
  <keyword>Letrozole</keyword>
  <keyword>Testosterone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
